Cited by 33Photodynamic Therapy Research StudiesNonmelanoma Skin Cancer StudiesPorphyrin Metabolism and Disorders

Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma

Open access
Pye, Andrew, Campbell, Sandra, Curnow, Alison·2008·Journal of Cancer Research and Clinical Oncology

Abstract

Purpose Methyl-aminolevulinate (MAL) photodynamic therapy (PDT) is a cancer therapy that combines the selective accumulation of a photosensitizer in tumor tissue with visible light (and tissue oxygen) to produce reactive oxygen species. This results in cellular damage and ablation of tumor tissue. Combining iron chelators with MAL has the potential to increase the accumulation of the photosensitizer protoporphyrin IX (PpIX) by reducing its bioconversion to heme. This paper investigates this method of enhancement both in vitro and for the first time clinically for the treatment of nodular basal cell carcinoma (BCC). Methods Enhancement of MAL-induced PpIX accumulation by the iron chelator CP94 was quantified fluorometrically in human cultured cells (including three dermatological cell types). An open, dose-escalating, pilot study was then conducted in patients with nodular BCC, to determine the safety of this pharmacological modification. Results Large enhancements in PpIX accumulation were observed in the cultured cells when co-incubated with the iron chelator CP94. Clinically the addition of CP94 was found to be feasible and safe. In addition greater reductions in tumor depth were observed in the CP94 co-incubated tumors. Conclusion Iron chelation by CP94 is an effective enhancer of MAL-induced PpIX accumulation in vitro. This method of enhancement was safely applied to a clinical PDT protocol with no unexpected adverse effects reported. Although the clinical investigation was only intended to be a small pilot to assess safety, enhancements in tumor clearance were observed both clinically and histologically when CP94 was included in the photosensitizing cream.

Integrity signals

Registry

Crossref · 10.1007/s00432-008-0358-6

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 38 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Pye, A., Campbell, S., & Curnow, A.
Affiliations
Royal Cornwall Hospital (GB)
Corresponding author
Pye, Andrew
Venue
Journal of Cancer Research and Clinical Oncology
Published
2008-02-01
Volume
134
Issue
8
Pages
841-849
ISSN
  • 0084-5353 (ISSN-L)
  • 0171-5216
  • 1432-1335
OpenAlex
W2058532864
Cited by
32
References
38
Citations by year
2026: 1 · 2024: 2 · 2023: 1 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 4 · 2016: 3 · 2015: 1 · 2014: 1 · 2013: 2
FWCI
3.38
Type
journal article
Language
en
Open access
Locations
  • Journal of Cancer Research and Clinical Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Open Research Exeter (University of Exeter) (submittedVersion)
  • Figshare (submittedVersion)
Funders
Menzies Centre for Australian Studies, King's College London, University of London
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
Keywords
methyl aminolevulinate, photodynamic therapy, iron chelation, protoporphyrin IX, photosensitizer accumulation, nodular basal cell carcinoma, treatment safety, dose escalation
MeSH terms
Aged, Aged, 80 and over, Aminolevulinic Acid, Carcinoma, Basal Cell, Basal Cell Carcinoma, Humans, Iron Chelating Agents, Middle Aged, Photochemotherapy, Pilot Projects, Protoporphyrins, Pyridones, Skin Neoplasms, Photosensitizing Agents, Cell Line, Tumor, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review